CYP1A2 and cholangiocarcinoma: The CYP1A2*1A/*1A polymorphism was found to decrease the risk for developing CCA in men, and when male patients were further stratified by smoking status, the polymorphism reduced the risk of developing CCA by a factor of 14 in smokers [29].